

N Gangat

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6752184/n-gangat-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

84
papers

2,113
citations

21
h-index

45
g-index

88
ext. papers

2,641
ext. citations

7
avg, IF

4.64
L-index

#	Paper	IF	Citations
84	A Population-Based Study of Acute Panmyelosis with Myelofibrosis in the United States: 2004-2015.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
83	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. <i>Blood Cancer Journal</i> , 2022 , 12, 7	7	1
82	Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
81	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 26	7	1
80	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.. <i>American Journal of Hematology</i> , 2022 ,	7.1	2
79	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
78	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. <i>Blood Cancer Journal</i> , 2022 , 12, 44	7	1
77	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
76	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3" .. <i>Blood Cancer Journal</i> , 2022 , 12, 55	7	1
75	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. <i>American Journal of Hematology</i> , 2021 ,	7.1	2
74	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2021 ,	4.5	3
73	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2021 , 97, E62	7.1	0
72	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. <i>American Journal of Hematology</i> , 2021 , 97, E35	7.1	2
71	A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. <i>American Journal of Hematology</i> , 2021 , 96, E464-E468	7.1	0
70	High-oxygen-affinity hemoglobinopathy-associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. <i>American Journal of Hematology</i> , 2021 , 96, 1647-1654	7.1	3
69	Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. <i>Blood Cancer Journal</i> , 2021 , 11, 170	7	0
68	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA + venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021 , 96, E108-E111	7.1	3

67	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. <i>Blood Cancer Journal</i> , 2021 , 11, 43	7	3
66	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 46	7	1
65	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 54	7	1
64	Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. <i>American Journal of Hematology</i> , 2021 , 96, E182-E184	7.1	6
63	Mutations and thrombosis in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2021 , 11, 77	7	8
62	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 781-789	7.1	17
61	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. <i>Blood Cancer Journal</i> , 2021 , 11, 122	7	0
60	Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women. <i>British Journal of Haematology</i> , 2021 , 195, 133-137	4.5	1
59	Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations. <i>American Journal of Hematology</i> , 2021 , 96, 354-366	7.1	4
58	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021 , 11, 49	7	11
57	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021 , 195, 413-416	4.5	1
56	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. <i>American Journal of Hematology</i> , 2021 , 96, 1472-1480	7.1	2
55	Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 1580-1586	7.1	2
54	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020 , 190, 244-248	4.5	1
53	Myelofibrosis biology and contemporary management. <i>British Journal of Haematology</i> , 2020 , 191, 152-170	7.5	21
52	Erythrocytosis associated with cerebral hemangiomas and multiple venous anomalies. <i>American Journal of Hematology</i> , 2020 , 95, 1224	7.1	3
51	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. <i>British Journal of Haematology</i> , 2020 , 189, 291-302	4.5	58
50	Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. <i>Blood Cancer Journal</i> , 2020 , 10, 122	7	8

49	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>American Journal of Hematology</i> , 2019 , 94, E231-E234	7.1	4
48	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. <i>American Journal of Hematology</i> , 2019 , 94, 767-779	7.1	27
47	Calculator-free point-of-care prognostication in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2019 , 94, E99-E101	7.1	
46	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2019 , 94, 299-305	7.1	5
45	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. <i>American Journal of Hematology</i> , 2019 , 94, 286-290	7.1	3
44	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019 , 94, 5-9	7.1	3
43	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E144-E146	7.1	
42	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. <i>American Journal of Hematology</i> , 2018 , 93, E146-E148	7.1	7
41	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E164-E167	7.1	1
40	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. <i>American Journal of Hematology</i> , 2018 , 93, 691-697	7.1	34
39	JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. <i>American Journal of Hematology</i> , 2018 , 93, E93-E96	7.1	14
38	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 835-838	4.5	23
37	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, E103-E107	7.1	
36	Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>American Journal of Hematology</i> , 2018 , 93, E27-E30	7.1	14
35	Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. <i>Leukemia</i> , 2018 , 32, 837-839	10.7	20
34	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. <i>American Journal of Hematology</i> , 2018 , 93, 65-73	7.1	37
33	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018 , 93, E355-E357	7.1	2
32	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. <i>American Journal of Hematology</i> , 2018 , 93, E235-E238	7.1	7

31	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. <i>American Journal of Hematology</i> , 2018 , 93, 1347-1357	7.1	7
30	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. <i>American Journal of Hematology</i> , 2018 , 93, 348-355	7.1	54
29	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. <i>British Journal of Haematology</i> , 2018 , 183, 678-684	7.5	10
28	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. <i>American Journal of Hematology</i> , 2018 , 93, E61-E64	7.1	23
27	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E398-E401	7.1	1
26	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , 2018 , 93, E401-E404	7.1	2
25	Mutations and karyotype predict treatment response in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, 1420-1426	7.1	18
24	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. <i>American Journal of Hematology</i> , 2018 , 93, 1474-1484	7.1	31
23	Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. <i>Blood Cancer Journal</i> , 2017 , 7, e538	7	16
22	Liver function test abnormalities and their clinical relevance in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2017 , 7, e557	7	1
21	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. <i>Blood Cancer Journal</i> , 2017 , 7, e550	7	14
20	Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. <i>Leukemia</i> , 2017 , 31, 2851-2852	10.7	16
19	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. <i>Blood Cancer Journal</i> , 2017 , 7, e584	7	49
18	Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. <i>Blood Cancer Journal</i> , 2017 , 7, 662	7	55
17	MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. <i>Blood Cancer Journal</i> , 2016 , 6, e487	7	19
16	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. <i>Blood Cancer Journal</i> , 2016 , 6, e472	7	32
15	Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. <i>Blood Cancer Journal</i> , 2016 , 6, e436	7	4
14	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. <i>Blood Cancer Journal</i> , 2016 , 6, e414	7	16

13	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2016 , 6, e385	7	83
12	Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. <i>Leukemia</i> , 2016 , 30, 1924-6	10.7	30
11	Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. <i>Blood Cancer Journal</i> , 2016 , 6, e415	7	8
10	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. <i>Leukemia</i> , 2016 , 30, 2273-2275	10.7	16
9	ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. <i>Blood Cancer Journal</i> , 2015 , 5, e315	7	23
8	Calreticulin mutations and long-term survival in essential thrombocythemia. <i>Leukemia</i> , 2014 , 28, 2300-3	10.7	79
7	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia</i> , 2014 , 28, 1804-10	10.7	213
6	Mutations and prognosis in primary myelofibrosis. <i>Leukemia</i> , 2013 , 27, 1861-9	10.7	520
5	Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. <i>Leukemia</i> , 2011 , 25, 82-8	10.7	150
4	The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. <i>Leukemia</i> , 2010 , 24, 110-4	10.7	56
3	MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. <i>Leukemia</i> , 2010 , 24, 859-60	10.7	21
2	Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. <i>Leukemia</i> , 2007 , 21, 270-6	10.7	161
1	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> ,	4.5	2